Document is current
Any future updates will be listed below
-
Authors
Patenaude, Bryan
Ballreich, Jeromie
-
Funding
Funding for this research was provided by:
Vaxart, Inc.
- License Information
-
More Information
Article History
Received: 18 April 2022
Accepted: 8 September 2022
First Online: 22 September 2022
Declarations
:
: Not applicable.
: Not applicable.
: The authors both received funding for this study from Vaxart, Inc. Vaxart, Inc. is currently developing an oral COVID-19 vaccine, the characteristics of which were utilized to define the oral vaccine discussed in this study. Apart from providing data on the characteristics of the oral vaccine under development, the funders had no influence over the study design, methods, statistical analyses, results, framing of results, decision to submit the manuscript for publication, or choice of journal.
